Dong-A Socio Group's honorary chairman passes away at 96
Kang Shin-ho, honorary chairman of Dong-A Socio Group, passed away Tuesday after battles with chronic diseases. He was 96.
Source: koreatimes.co.kr
Donga Socio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Donga Socio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Donga Socio Today - Breaking & Trending Today
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
BOSTON, Aug. 14, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of... -Today at 08:02 am- MarketScreener
Source: marketscreener.com
Dong-A ST CO., Ltd: Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP Biosimilar DA-3880
- Dong-A building a foundation for expanding its biosimilar business through license-out and supply agreements to Türkiye, Brazil and Mexico - Creating a synergy effect with STgen Bio, an affiliated
Source: finanznachrichten.de
ST Pharm in talks with Moderna over contract manufacturing of COVID-19 vaccine
By Baek Byung-yeul, Kim Yoo-chul Korean biotechnology firm, ST Pharm, is in talks with Moderna to produce messenger RNA (mRNA) COVID-19 vaccines, sources familiar with the matter told The Korea Times, Tuesday. "ST Pharm is in talks with Moderna to produce its mRNA vaccines following approval by the Ministry of Food and Drug Safety," one source said on condition of anonymity. ST Pharm declined to comment on the possibility of signing a contract manufacturing organization (CMO) deal with Moderna. "ST Pharm plans to apply liquid nanoparticle (LNP)-based drug substance technology for its RNA va...
Source: koreatimes.co.kr
Meiji Announces Promising Phase I Results for Ustekinumab Biosimilar and Initiation of Phase III Clinical Trial | Goodwin
On May 21, 2021, Meiji Seika Pharma Co, Ltd. announced that phase I clinical trials of DMB-3115, its proposed ustekinumab (STELARA®) biosimilar, demonstrated bioequivalence to reference...
Source: jdsupra.com